WallStSmart

Abbott Laboratories (ABT)vsEnovis Corp (ENOV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 1881% more annual revenue ($45.13B vs $2.28B). ABT leads profitability with a 13.9% profit margin vs -49.9%. ABT appears more attractively valued with a PEG of 1.30. ENOV earns a higher WallStSmart Score of 57/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 4.7Quality: 6.0
Piotroski: 4/9Altman Z: 2.71

ENOV

Buy

57

out of 100

Grade: C

Growth: 8.0Profit: 3.0Value: 6.3Quality: 5.5
Piotroski: 4/9Altman Z: -0.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTSignificantly Overvalued (-28.5%)

Margin of Safety

-28.5%

Fair Value

$70.89

Current Price

$91.07

$20.18 premium

UndervaluedFair: $70.89Overvalued
ENOVUndervalued (+34.9%)

Margin of Safety

+34.9%

Fair Value

$35.03

Current Price

$23.78

$11.25 discount

UndervaluedFair: $35.03Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT1 strengths · Avg: 9.0/10
Market CapQuality
$151.49B9/10

Large-cap with strong market position

ENOV2 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

EPS GrowthGrowth
153.1%10/10

Earnings expanding 153.1% YoY

Areas to Watch

ABT1 concerns · Avg: 2.0/10
EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

ENOV4 concerns · Avg: 3.0/10
PEG RatioValuation
1.904/10

Expensive relative to growth rate

Market CapQuality
$1.25B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
3.6%3/10

Operating margin of 3.6%

Return on EquityProfitability
-77.0%2/10

ROE of -77.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap. PEG of 1.30 suggests the stock is reasonably priced for its growth.

Bull Case : ENOV

The strongest argument for ENOV centers on Price/Book, EPS Growth.

Bear Case : ABT

The primary concerns for ABT are EPS Growth.

Bear Case : ENOV

The primary concerns for ENOV are PEG Ratio, Market Cap, Operating Margin.

Key Dynamics to Monitor

ABT profiles as a value stock while ENOV is a turnaround play — different risk/reward profiles.

ENOV carries more volatility with a beta of 1.49 — expect wider price swings.

ABT is growing revenue faster at 7.8% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Bottom Line

ENOV scores higher overall (57/100 vs 56/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Enovis Corp

HEALTHCARE · MEDICAL DEVICES · USA

Enovis Corporation is a global medical technology company. The company is headquartered in Wilmington, Delaware.

Want to dig deeper into these stocks?